National Hellenic Research Foundation, 11635 Athens, Greece.
Department of Surgical Pathology, Saint Savvas Anticancer Hospital of Athens, 11522 Athens, Greece.
Int J Mol Med. 2021 Apr;47(4). doi: 10.3892/ijmm.2021.4870. Epub 2021 Feb 4.
Inflammation is the most common cause of most acute and chronic debilitating diseases. Towards unveiling novel therapeutic options for patients with such complications, N‑bromotaurine (TauNHBr) has emerged as a potential anti‑inflammatory agent; however, its therapeutic efficacy is hindered due to its relatively poor stability. To address this challenge, the present study focused on examining the effects of a stable active bromine compound, named bromamine T (BAT). The present study examined the protective properties of BAT against lipopolysaccharide (LPS)‑mediated inflammation , by using LPS‑stimulated murine J774.A1 macrophages (Mφs), as well as , by using a murine LPS‑mediated air‑pouch model. Additionally, its efficacy was compared with that of taurine, a known potent anti‑inflammatory molecule. In LPS‑stimulated J774A.1 Mφs, BAT and taurine were very effective in reducing the secretion of pro‑inflammatory mediators. The experiments indicated that LPS‑mediated inflammation was attenuated due to the protective properties of BAT and of taurine, probably through the inhibition of phosphorylated p65 NF‑κB subunit (Ser 536) nuclear translocation. The experiments also revealed that BAT and taurine inhibited LPS‑mediated inflammation by reducing total cell/polymorphonuclear cell (PMN) infiltration in the air‑pouch and by decreasing pouch wall thickness. The analysis of exudates obtained from pouches highlighted that the inhibitory effects of BAT and taurine on the secretion of pro‑inflammatory cytokines were similar to those observed . Notably, the effect of BAT at the highest concentration tested was superior to that of taurine at the highest concentration. Taken together, the findings of the present study indicate that BAT prevents the LPS‑induced inflammatory response both and .
炎症是大多数急性和慢性衰弱性疾病的最常见原因。为了为患有此类并发症的患者揭示新的治疗选择，N-溴代牛磺酸（TauNHBr）已成为一种有潜力的抗炎药；然而，由于其相对较差的稳定性，其治疗效果受到阻碍。为了解决这一挑战，本研究集中研究了一种稳定的活性溴化合物，名为溴胺 T（BAT）的作用。本研究通过使用脂多糖（LPS）刺激的小鼠 J774.A1 巨噬细胞（Mφs）以及通过使用小鼠 LPS 介导的气囊模型，检查了 BAT 对 LPS 介导的炎症的保护特性。此外，将其功效与已知的强效抗炎分子牛磺酸进行了比较。在 LPS 刺激的 J774A.1 Mφs 中，BAT 和牛磺酸非常有效地减少了促炎介质的分泌。实验表明，由于 BAT 和牛磺酸的保护特性，LPS 介导的炎症减轻了，可能是通过抑制磷酸化 p65 NF-κB 亚基（Ser536）核易位。实验还表明，BAT 和牛磺酸通过减少气囊中的总细胞/多形核细胞（PMN）浸润和降低囊壁厚度来抑制 LPS 介导的炎症。从囊中获得的渗出物分析表明，BAT 和牛磺酸对促炎细胞因子分泌的抑制作用与观察到的相似。值得注意的是，在测试的最高浓度下，BAT 的作用优于牛磺酸的最高浓度。总之，本研究的结果表明，BAT 可预防 LPS 诱导的炎症反应。
